Compare FC & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FC | THAR |
|---|---|---|
| Founded | 1983 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.5M | 193.3M |
| IPO Year | 1992 | 2022 |
| Metric | FC | THAR |
|---|---|---|
| Price | $17.42 | $4.75 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $26.00 | N/A |
| AVG Volume (30 Days) | 129.0K | ★ 1.5M |
| Earning Date | 04-01-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $262,026,000.00 | N/A |
| Revenue This Year | $3.02 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.04 | $0.95 |
| 52 Week High | $36.55 | $9.08 |
| Indicator | FC | THAR |
|---|---|---|
| Relative Strength Index (RSI) | 34.00 | 60.77 |
| Support Level | $18.42 | $4.15 |
| Resistance Level | $18.92 | $4.83 |
| Average True Range (ATR) | 0.96 | 0.61 |
| MACD | -0.42 | -0.02 |
| Stochastic Oscillator | 1.13 | 48.64 |
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.